World’s Largest BiOPV Roof Installation Using Heliatek’s HeliaSol®

World’s Largest BiOPV Roof Installation Using Heliatek’s HeliaSol®

Canada NewsWire

LA ROCHELLE, France, Nov. 15, 2017 /CNW/ – Today ENGIE, Heliatek and the Department of Charentes-Maritimes inaugurated the world’s largest BiOPV installation on a roof. 500 m² of Heliatek’s solar films were installed on the roof of the “Pierre Mendes France” middle school in La Rochelle, France. With 3 different lengths of 2, 4 and 5.7 meters, nearly 400 films were applied in record time. The result is the largest BiOPV – Building integrated Organic PhotoVoltaic – roof installation, worldwide to date, and proof of the ease and speed that these solar films can be installed.

(Logo: http://mma.prnewswire.com/media/604604/Heliatek_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/604603/Heliatek_HeliaSol.jpg )
(Photo: http://mma.prnewswire.com/media/604602/Heliatek_OPV_project_on_a_roof.jpg )

Heliatek’s HeliaSol® “ready-to-use” film was used on a roof installation for the first time. With a self-adhesive back and preconfigured wiring, HeliaSol® is mounted directly onto existing roof surfaces and only needs to be electrically connected. Taking into account the preparation time, 6 people needed only 8 hours to install 500m² of HeliaSol® as deployment took just over 2 minutes per film. With an installed power of 22.5 kWp, about 23.8 MWh will be generated annually, representing approximately 15% of the school’s electricity demand.

HeliaSol® is a “ready-to-use” solar product solution for the retrofitting market of roof surfaces and facades. HeliaSol® is suitable for all energy-saving renovation projects where restrictions on weight, statics, access, insulation, guarantee or penetration of the roof play a role in product selection. This French installation is the first step in preparing for a general market entry.

Heliatek is anticipating market developments and increased requirements to integrate existing surfaces into the energy system of a building. “Light roofs, which usually do not allow for standard PV technology, can now produce green electricity with our HeliaSol®. Thanks to our strong partner and investor ENGIE, we were able to rapidly realize this exciting project,” says Thibaud Le Séguillon, Heliatek’s CEO.

ENGIE is assuming a leading role in the transformation of the energy sector. “Renewable energy is an essential part of our strategy of decarbonization, decentralization as well as digitalization of energy. Almost half of the energy consumption comes from the buildings sector. Buildings that couldn’t previously be used for energy production will be able to cover their own electricity requirements. With Heliatek’s technology, they will contribute to a decentralized and green energy supply,” says Isabelle Kocher, ENGIE’s CEO.

http://www.engie.com

http://www.heliatek.com

HeliaSol and
HeliaFilm
are
registered trademark
s
of Heliatek GmbH.

SOURCE Heliatek

View original content: http://www.newswire.ca/en/releases/archive/November2017/15/c7761.html

Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

PR Newswire

WASHINGTON, Nov. 10, 2017 /PRNewswire/ – Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union.  In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum™ MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum™ MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.


About Fanapt®

For full U.S. Prescribing Information for Fanapt®, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.

Russian Hospitality: 137th Inter-Parliamentary Union Assembly Leaves Impression on World’s Parliamentarians

Logo

Russian Hospitality: 137th Inter-Parliamentary Union Assembly Leaves Impression on World’s Parliamentarians

PR Newswire

ST PETERSBURG, Russia, November 9, 2017 /PRNewswire/ —

The 137th Inter-Parliamentary Union Assembly set a high standard with its level of organisation and the amount of positive feedback that it provoked. More than 2,500 participants, over 160 delegations and 400 journalists took part in the event, which was held from 14 to 18 October in St Petersburg. Representatives from overseas remarked on the number of members and deputy members of parliament present, and on their active participation in the Assembly’s work.

To view the Multimedia News Release, please click:

https://www.multivu.com/players/uk/8218351-russia-137th-inter-parliamentary-union/

Chairperson of the Council of the Federation Valentina Matvienko noted the high level of professionalism and coordination shown by the Assembly’s organisers, and thanked all involved for a job well done. “It is the shared opinion of all participants that this Assembly, in terms of its scale and success, has no precedent in the more than one-hundred-year history of the Inter-Parliamentary Union. I am confident that the forum will become a bright page in the history of international parliamentary cooperation, and will doubtless strengthen Russia’s standing on the international stage”, she remarked.

A film on the achievements and outcomes of the 137th Inter-Parliamentary Union Assembly was prepared at the conclusion of the event. It includes some introductory information about the host city, St Petersburg, parliamentarians’ impressions of the Assembly, clips from key events in the business programme, and a kaleidoscopic presentation of major events in the accompanying cultural programme.

An English-language version of the concluding film is available at the following link: https://yadi.sk/i/71E81PzD3PNWt9

Roscongress Foundation a major organizer of congress and exhibition events 

The Roscongress Foundation was founded in 2007 with the aim of facilitating the development of Russias economic potential and strengthening the countrys image by organizing conventions, exhibitions, and public events.The Foundation develops substantive content for such events, providing companies and organizations with advice, information, and expert guidance, and offering comprehensive evaluation, analysis, and coverage of the Russian and global economic agendas.It offers administrative services and promotional support for business projects and helps to attract investment, including in the form of public-private partnerships. 

Today, its annual programme includes events held from Montevideo to Vladivostok, offering an opportunity to bring together global business leaders, experts, the media, and government officials in one place, creating favourable conditions for dialogue and the promotion of new ideas and projects, and assisting in the creation of social enterprise and charity projects. 

http://www.roscongress.org

     (Photo: http://mma.prnewswire.com/media/598816/Inter_Parliamentary_Union.jpg )

Video: 
     https://www.multivu.com/players/uk/8218351-russia-137th-inter-parliamentary-union/

SOURCE Inter-Parliamentary Union (IPU)